|
|
|
|
|
|
|
|
|
18.08.26 - 14:09
|
Longevica Therapeutics Appoints Ex-Genentech Biotech Veteran Dr. Prasun Mishra as CEO to Advance World′s Largest $13 Million Mammalian Longevity Study Toward Clinical Development (Business Wire)
|
|
|
Former Genentech/Roche and NIH Leader Appointed CEO to Drive Longevica Therapeutics Into IND-Enabling Development Following Completion of World's Largest Mammalian Longevity StudySAN FRANCISCO & NEW YORK--(BUSINESS WIRE)--$AI #AI--Longevica Therapeutics, Inc. ("Longevica"), a preclinical biotechnology company pioneering target discovery and small-molecule therapeutics from full-lifespan mammalian geroscience, today announced the appointment of biopharmaceutical executive Dr. Prasun Mishra as Chief Executive Officer and member of its Board of Directors. The appointment marks Longevica's strategic transition from foundational discovery to systematic drug development, accelerating the translation of its proprietary mammalian longevity dataset into clinical pipeline candidates.
Dr. Mishra's appointment follows the completion of Longevica's landmark four-year, $13 million in vivo mammalian screening program conducted at The Jackson Laboratory, which systematically evaluated 1,033 small-molecule compounds a...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.08.26 - 14:54
|
wikifolio-Trader Sebastian "Bastian24" Steyer: "Aktiv bedeutet nicht: Ständig hin und her" - Kandidaten: Hitachi, NXP, Aurubis (BRN)
|
|
|
"Auch wenn man gar nicht so viel aktiv an der Börse ist, kann man trotzdem gute Renditen erwirtschaften. Aktiv bedeutet nicht: Ständig hin und her." Sebastian Steyers wikifolio "Qualitätsaktien aktiv" ( https://go.brn-ag.de/242 ) funktioniert über Diversifikation und Korrelation. So ist zum Beispiel Nvidia deutlich höher gewichtet als Rheinmetall. 46 Aktien stecken derzeit im Depot, darunter Cash Cows wie Amazon, Alphabet oder Apple. "Seit Jahresbeginn sind wir bei 11,7 % Rendite. Unter den großen Gewinnern: Applied Materials, Roche, Taiwan Semiconductor, Equinor, United Utilities." Unter den Kauf- und Aufstockungskandidaten befinden sich Hitachi, Aurubis, Siemens und NXP Semiconductors. "Mich reizt das Thema Robotik. Aurubis ist ein deutscher Top Player in der Kupferindustrie. Bei Siemens mache ich mir überhaupt keine Sorgen. NXP ist ein Philips-Spin-Off sowie eine Top-Aktie mit relativ moderater Bewertung."...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.08.26 - 22:06
|
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights (Business Wire)
|
|
|
Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million
Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash
Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2b PADOVA clinical trial published in The Lancet
Multiple research collaborations with industry partners ongoing to explore the potential of our CYTOPE® technology over the next 12 to 24 months
DUBLIN--(BUSINESS WIRE)--$PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results f...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
